Zepzelca (lurbinectedin)

Numéro de dossier de l’APP: 22128
État des négociations:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy
Promoteur/fabricant:
Jazz Pharmaceuticals Canada Inc.
Numéro de projet de l’ACMTS:
PC0281
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation:
Not Applicable